Tibet Weixinkang Medicine Co., Ltd.

XSSC:603676 Stock Report

Market Cap: CN¥4.6b

Tibet Weixinkang Medicine Past Earnings Performance

Past criteria checks 3/6

Tibet Weixinkang Medicine has been growing earnings at an average annual rate of 35.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 14.9% per year. Tibet Weixinkang Medicine's return on equity is 16.7%, and it has net margins of 19.7%.

Key information

35.3%

Earnings growth rate

34.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate14.9%
Return on equity16.7%
Net Margin19.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Tibet Weixinkang Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:603676 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,256247368119
30 Jun 241,206243366121
31 Mar 241,290249391122
31 Dec 231,323214402113
30 Sep 231,393236433102
30 Jun 231,48020847790
31 Mar 231,43419847078
31 Dec 221,39917748472
30 Sep 221,34916546157
30 Jun 221,20214642749
31 Mar 221,14111641844
31 Dec 211,0349638838
30 Sep 211,0019635433
30 Jun 219348232827
31 Mar 217946629422
31 Dec 207165826321
30 Sep 206595625314
30 Jun 206754825820
31 Mar 207164626323
31 Dec 197415627526
30 Sep 198175330326
30 Jun 197935431225
31 Mar 197476028724
31 Dec 187467327021
30 Sep 186168922621
30 Jun 185329315331
31 Mar 1849711515727
31 Dec 1742010213823
30 Sep 1742111312218
30 Jun 174021151440
31 Mar 174251141730
31 Dec 164261151480
31 Dec 154401131530
31 Dec 143911071350

Quality Earnings: 603676 has a large one-off gain of CN¥57.1M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 603676's current net profit margins (19.7%) are higher than last year (17%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603676's earnings have grown significantly by 35.3% per year over the past 5 years.

Accelerating Growth: 603676's earnings growth over the past year (4.6%) is below its 5-year average (35.3% per year).

Earnings vs Industry: 603676 earnings growth over the past year (4.6%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 603676's Return on Equity (16.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:20
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet Weixinkang Medicine Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaxi XuIndustrial Securities Co. Ltd.